BioCentury | Jan 8, 2021
Product Development

Caplan sees a host of bioethical turning points coming out of the pandemic

The reckoning that will come after the pandemic will see broad if not tectonic shifts in drug development, from clinical trial conduct to scientific publishing, according to bioethicist Arthur Caplan....
BioCentury | Sep 10, 2020
Product Development

Master protocols should not be a one-off phenomenon confined to COVID-19

This is the fourth article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development. ...
BioCentury | Aug 18, 2020
Product Development

I Want KaNDy, plus Sputnik V & M&A amid COVID-19: a BioCentury podcast

Bayer’s deal with KaNDy could be a sign that companies are finally paying attention to Women’s health, a field in which biotechs have long struggled to raise venture money. On the latest edition of the...
BioCentury | Aug 14, 2020

Industry executives see M&A opportunities during COVID-19

M&A drives growth, and smaller companies are likely continue to be picked off rather than grow into big biotechs, according to a panel of industry executives. BioCentury hosted a webinar on Aug. 12...
BioCentury | Aug 7, 2020

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

Heading into the second half of the year with cautious optimism, drug developers see opportunities for dealmaking created by COVID-19, as well as challenges. If their predictions are right, infectious deals could surpass cancer transactions....
BioCentury | Jun 24, 2020

Gilead gains access to tumor myeloid targets via Pionyr partnership

Gilead’s tie-up with Pionyr marks the big biotech’s fifth cancer deal this year and gives it access to mAbs against immunosuppressive tumor myeloid cells. In an agreement announced Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) will pay...
BioCentury | Jun 11, 2020

In course correction, AbbVie steers toward innovation with Genmab deal

AbbVie’s Genmab deal gives it a ticket to one of the hottest modality spaces, albeit as a latecomer. The pharma gains bispecific antibodies to add to its ADCs and standard mAbs, extending its tool kit...
BioCentury | Jun 4, 2020

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

Novo Ventures has led a $55 million series B round for NodThera, a trans-Atlantic biotech operating in an area ripe for takeouts -- the inflammasome. The biotech's lead program targets NLRP3, a target explored by...
BioCentury | May 27, 2020
Top Story

Arcus keeps its independence in deal that gives Gilead access to targets ripe for combinations

Gilead’s partnership with Arcus gives it access to a pipeline ripe for immuno-oncology combinations around closely watched targets, such as TIGIT. But the agreement doesn’t mirror Gilead’s last deal, in which partnering negotiations with Forty...
BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

...NASDAQ:GNPX), has a preclinical diabetes gene therapy. It licensed the AAV vector delivering Pdx1 and MafA...
...GK) - Glucokinase GLP-1R 9GLP1R) - Glucagon-like peptide-1 receptor IGF-1 - Insulin-like growth factor-1 MAFA (RIPE3b1...
Items per page:
1 - 10 of 160